Gastroenterology

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Sanofi's Dupixent® (dupilumab) Granted Breakthrough Therapy Designation for Eosinophilic Esophagitis By FDA

Lead Product(s): Dupilumab

Therapeutic Area: Gastroenterology Product Name: Dupixent

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 14, 2020

Details:

Dupixent is the first and only biologic to show positive and clinically-meaningful Phase 3 results in patients 12 years and older with eosinophilic esophagitis (EoE).

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Sanofi to present growth opportunities and development strategy for Dupixent® (dupilumab) in type 2 inflammatory diseases

Lead Product(s): Dupilumab

Therapeutic Area: Gastroenterology Product Name: Dupixent

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 11, 2020

Details:

Dupixent’s unique mechanism of action simultaneously inhibits IL-4 and IL-13. Recent evidence further supports additional clinical uses in diseases driven by type 2 inflammation including Eosinophilic Esophagitis and a subset of Chronic Obstructive Pulmonary Disease .

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Arcadia Consumer Healthcare Acquires Iconic Over-the-Counter Anti-Diarrheal Medicine Kaopectate®

Lead Product(s): Bismuth Subsalicylate

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Arcadia Consumer Healthcare

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition March 20, 2020

Details:

Acquisition further strengthens Arcadia's consumer healthcare product portfolio.

Napo Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Third Amendment to Purchase Agreement with Oasis Capital, LLC

Lead Product(s): Crofelemer

Therapeutic Area: Gastroenterology Product Name: Mytesi

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Oasis Capital

Deal Size: $2.3 million Upfront Cash: Undisclosed

Deal Type: Agreement September 10, 2020

Details:

Oasis agreed to purchase additional accounts receivable of the Company related to the sales of the Company's Mytesi® drug product to Cardinal Health for the period of August 11, 2020 through September 3, 2020.

Takeda Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Takeda Provides Update on U.S. Development Program for the Subcutaneous Formulation of ENTYVIO® for Moderate to Severe Ulcerative Colitis

Lead Product(s): Vedolizumab

Therapeutic Area: Gastroenterology Product Name: Entyvio

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 02, 2020

Details:

Takeda has received Complete Response Letter from the U.S. FDA in response to the submission of a BLA for an investigational subcutaneous formulation of Entyvio® (vedolizumab) for maintenance therapy in adults with moderate to severe ulcerative colitis (UC).

Abivax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Abivax Reports Long-Lasting Two-Year Efficacy and Safety Data from ABX464 Ulcerative Colitis Phase 2a Maintenance Study

Lead Product(s): 8-Chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine

Therapeutic Area: Gastroenterology Product Name: ABX464

Highest Development Status: Phase II Product Type: Small molecule

Find

Find Gastroenterology Clinical Drug Pipeline Developments & Deals

Product Type

Development Status

Sanofi

Sanofi's Dupixent® (dupilumab) Granted Breakthrough Therapy Designation for Eosinophilic Esophagitis By FDA

Sanofi

Sanofi to present growth opportunities and development strategy for Dupixent® (dupilumab) in type 2 inflammatory diseases

Sanofi

Arcadia Consumer Healthcare Acquires Iconic Over-the-Counter Anti-Diarrheal Medicine Kaopectate®

Napo Pharmaceuticals

Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Third Amendment to Purchase Agreement with Oasis Capital, LLC

Takeda Pharmaceutical

Takeda Provides Update on U.S. Development Program for the Subcutaneous Formulation of ENTYVIO® for Moderate to Severe Ulcerative Colitis

Abivax

Abivax Reports Long-Lasting Two-Year Efficacy and Safety Data from ABX464 Ulcerative Colitis Phase 2a Maintenance Study